APRO 88 Catheter
Alembic, LLC · Decision date Oct 6, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 2026-10-06 for the APRO 88 Catheter, submitted by Alembic, LLC of Mountain View, California, under 510(k) number K261938. The device falls under regulation 870.1250 with the classification name Catheter, Percutaneous, Neurovasculature, primary product code QJP and subsequent product code DQY. The regulation medical specialty is listed as Cardiovascular, while the 510(k) review panel is Neurology. The application was received 06/10/2026 as a Traditional 510(k), was not reviewed by a third party, and was not a combination product.
SESE means FDA cleared the submission as substantially equivalent to a legally marketed predicate device; it is not a PMA approval. The public record does not identify the predicate device, the specific components or materials, or any indications for use, and no summary or decision statement is included in the available text. A Predetermined Change Control Plan was not authorized, so no pre-authorized modification scope is recorded. The same decision appears in FDA's final-decision listing dated 06 October 2026.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 6, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K261938
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Alembic, LLC
- Product code
- QJP
- Decision code
- SESE
- Decision date
- Oct 6, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Catheter, Percutaneous, Neurovasculature.
- Applicant
- Alembic, LLC
- Product code
- QJP
- FDA device class
- 2
FDA decision timeline
K261938 received
Application receipt date recorded by FDA.
K261938 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code QJP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
NeuroSheathK261449 | Perfuze, Ltd. | 510(k) clearance | Nov 5, 2026 | FDA |
| Stryker Neurovascular | 510(k) clearance | Oct 9, 2026 | FDA | |
OAB Delivery CatheterK253422 | Cognition Medical Corp. | 510(k) clearance | Oct 2, 2026 | FDA |
| Route 92 Medical, Inc. | 510(k) clearance | Sep 16, 2026 | FDA | |
70 NeuGlide CatheterK262277 | Piraeus Medical, Inc. | 510(k) clearance | Sep 4, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Alembic, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Mountain View, CA
Sources and methodology
- Original FDA record: K261938
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

